Zhejiang Angda Jiuli Biopharmaceutical

Zhejiang Angda Jiuli Biopharmaceutical is a Chinese biotechnology company specializing in the development and large-scale production of recombinant human albumin (rHA). Established as a strategic joint venture between Angda Biopharmaceutical and the Jiuli Group, the company focuses on addressing the chronic shortage of plasma-derived albumin in the Chinese market. The company utilizes a proprietary yeast-based expression platform to manufacture high-purity, animal-derived component-free albumin suitable for both therapeutic injections and pharmaceutical excipients. Its primary facility, located in Huzhou, Zhejiang, is a major industrialization base designed to meet international GMP standards with a significant annual production capacity. The company's lead candidate, a recombinant human albumin injection, is currently undergoing clinical trials to evaluate its efficacy in treating conditions such as hypoalbuminemia and liver cirrhosis.